The Abdominal Aortic Aneurysm market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast
Artivion (NYSE:AORT – Get Rating) and INVO Bioscience (NASDAQ:INVO – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Institutional and Insider Ownership 82.2% of Artivion shares are owned […]
Equities analysts expect that Artivion, Inc. (NYSE:AORT – Get Rating) will post earnings of $0.03 per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Artivion’s earnings, with the lowest EPS estimate coming in at $0.00 and the highest estimate coming in at $0.05. Artivion reported earnings of ($0.08) […]
/PRNewswire/ Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022.